biotech
Vitespen (Oncophage) Vaccine Shows Promising Results Against Glioma
Filed in archive Drugs, Vaccines and Therapeutics by ruth on November 17, 2006
Vitespen (Oncophage) Vaccine Shows Promising Results Against Glioma
Scientists from the UCSF Medical Center have shown that vitespen (trademarked as Oncophage), a vaccine developed for the treatment of glioma seems to be effective. Glioma, a type of tumor arising from glial cells, commonly involves the brain.
Derived from each individual's tumor, vitespen contains the "fingerprint" of the patient's particular cancer and is designed to reprogram the body's immune system to target only cancer cells bearing this fingerprint. The vaccine is intended to leave healthy tissue unaffected and limit the debilitating side effects typically associated with traditional cancer treatments such as chemotherapy and radiation therapy.

Vitespen is also on trials, and has received fast track and orphan drug designations from the Food and Drug Administration, in both metastatic melanoma (skin cancer) and renal cell carcinoma (kidney cancer).
More details of the clinical trials from the UCSF report.

[Photo: Antigenics]

Permalink: Vitespen (Oncophage) Vaccine Shows Promising Results Against Glioma
Tags: vaccine  glioma  brain+tumor  tumor  cancer  oncophage  vitespen  biotech  oncophage+vaccine 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/42931
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Vitespen (Oncophage) Vaccine Shows Promising Results Against Glioma:

  • Currently 8.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.00 out of 7 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!